Researchers at the University of Michigan Kellogg Eye Center have developed a new nanoparticle that uses a tumor cell’s protective mechanism against itself — short-circuiting tumor cell metabolism and killing tumor cells.
One of the most common cancer-causing genes has continuously stymied researchers’ efforts to develop treatments against it. Now, researchers have dug deeper and exposed a key interaction that may contribute to why mutations in KRAS lead to cancer.
Cancer Center researcher Max S. Wicha has received a $6.5 million Outstanding Investigator Award to study cancer stem cells, the small number of cells within a tumor that fuel its growth and spread.
In response to low national vaccination rates for the human papillomavirus, the University of Michigan Comprehensive Cancer Center has joined 69 of the nation’s top cancer centers in issuing a statement urging for increased HPV vaccination for the prevention of cancer.
Nearly 15 percent of patients diagnosed with colorectal cancer were younger than 50, the age at which screening recommendations begin.
A new University of Michigan study found that feeding rats a "nisin milkshake" killed 70-80 percent of head and neck tumor cells after nine weeks and extended survival, said Dr. Yvonne Kapila, a professor at the University of Michigan School of Dentistry.
Millendo Therapeutics, a University of Michigan startup company, announced today that it has entered into an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.
Researchers found that only 55 percent of colorectal cancer patients who were employed at the time of diagnosis retained their jobs after treatment. Patients who had paid sick leave were nearly twice as likely to retain their jobs as those without paid sick leave.
Researchers have identified potential genetic alterations in penile cancer that could pave the way for targeted treatments. The new study describes a complex landscape that could suggest potential clinical trials of targeted therapies – and potential limitations in some patients.
New studies add to questions about predicting whether tamoxifen will be effective in an individual breast cancer patient.